Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed in its monthly return to Hong Kong Exchanges and Clearing Limited that it repurchased a total of 204,200 H shares in May 2026, holding all repurchased stock as treasury shares.

Key transaction data • 27 May 2026: 134,200 shares bought back at an average HK$16.3092 each, involving HK$2.19 million. • 28 May 2026: 70,000 shares bought back at an average HK$16.5227 each, involving HK$1.16 million. Aggregate consideration for the two-day programme was approximately HK$3.35 million.

Share capital movement • Issued H shares (excluding treasury) fell from 224.57 million to 224.36 million, a decrease of 204,200 shares, equivalent to 0.09% of the outstanding total. • Treasury shares increased from 2.50 million to 2.71 million. • Total issued share count, including treasury shares, remained unchanged at 227.07 million, matching the company’s authorised share capital of RMB 227.07 million (par value: RMB 1 per share).

Public float position Despite the repurchases, QYUNS-B confirmed that it continues to meet the Main Board’s minimum public float requirement of 25% of issued H shares, as at 31 May 2026.

Capital management context The share buy-backs were executed under a mandate approved on 20 June 2025. No share options, warrants, convertibles or other equity-linked instruments were issued, exercised, or converted during the month.

With its authorised share capital fully utilised and a modest increase in treasury holdings to 1.19% of total issued shares, QYUNS-B’s latest filing underscores continued use of on-market repurchases as a capital management tool while maintaining regulatory compliance on public float levels.